Checkpoint Therapeutics' shares rise as FDA accepts resubmission of cosibelimab for advanced cutaneous squamous cell carcinoma treatment.

Checkpoint Therapeutics shares rise after FDA accepts resubmission of cosibelimab, an anti-PD-L1 antibody, for treating advanced cutaneous squamous cell carcinoma. The drug is intended for adults with metastatic or locally advanced cSCC who aren't candidates for curative surgery or radiation. This news comes after resubmission was accepted as a complete response to FDA's December 2023 comments.